Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Yuliya Lytvyn(University Health Network), David Z.I. Cherney(University Health Network), Louis Handoko(Amsterdam University Medical Centers), Kevin D. Burns(University of Ottawa), Leif E. Lovblom(University of Toronto), Hiddo J.L. Heerspink(University Medical Center Groningen), Charlotte M. Mosterd(Amsterdam University Medical Centers), Vikas S. Sridhar(University Health Network), Daniël H. van Raalte(Amsterdam University Medical Centers), Luxcia Kugathasan(University of Toronto), Eva M. Boorsma(University Medical Center Groningen), Hongyan Liu, Adriaan A. Voors(The Medical Center of Aurora), Tosin Osuntokun(University Health Network), John S. Floras(University Health Network), Rosalie A. Scholtes
Cited by 5
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990